

Melissa S Love

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/399798/publications.pdf>

Version: 2024-02-01

18
papers

692
citations

759233

12
h-index

839539

18
g-index

19
all docs

19
docs citations

19
times ranked

1119
citing authors

#	ARTICLE	IF	CITATIONS
1	The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 10750-10755.	7.1	165
2	Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7015-7020.	7.1	94
3	A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis. PLoS Neglected Tropical Diseases, 2017, 11, e0005373.	3.0	91
4	Platelet Factor 4 Activity against P.Âfalciparum and Its Translation to Nonpeptidic Mimics as Antimalarials. Cell Host and Microbe, 2012, 12, 815-823.	11.0	71
5	Bicyclic azetidines kill the diarrheal pathogen <i>Cryptosporidium</i> in mice by inhibiting parasite phenylalanyl-tRNA synthetase. Science Translational Medicine, 2020, 12, .	12.4	45
6	Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis. Nature Communications, 2019, 10, 2816.	12.8	43
7	A Host GPCR Signaling Network Required for the Cytolysis of Infected Cells Facilitates Release of Apicomplexan Parasites. Cell Host and Microbe, 2013, 13, 15-28.	11.0	37
8	Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosis. International Journal for Parasitology, 2017, 47, 753-763.	3.1	30
9	A suite of phenotypic assays to ensure pipeline diversity when prioritizing drug-like Cryptosporidium growth inhibitors. Nature Communications, 2019, 10, 1862.	12.8	28
10	Emerging treatment options for cryptosporidiosis. Current Opinion in Infectious Diseases, 2021, 34, 455-462.	3.1	17
11	Phenotypic screening techniques for<i>Cryptosporidium</i>drug discovery. Expert Opinion on Drug Discovery, 2021, 16, 59-74.	5.0	16
12	Iron limitation in M. tuberculosis has broad impact on central carbon metabolism. Communications Biology, 2022, 5, .	4.4	13
13	Herbicidins from <i>Streptomyces</i> sp. CB01388 Showing Anti-<i>Cryptosporidium</i> Activity. Journal of Natural Products, 2018, 81, 791-797.	3.0	12
14	Pharmacological and genetic activation of cAMP synthesis disrupts cholesterol utilization in Mycobacterium tuberculosis. PLoS Pathogens, 2022, 18, e1009862.	4.7	11
15	Repurposing Infectious Disease Hits as Anti-<i>Cryptosporidium</i> Leads. ACS Infectious Diseases, 2021, 7, 1275-1282.	3.8	8
16	Pharmacokinetics and Pharmacodynamics of Clofazimine for Treatment of Cryptosporidiosis. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0156021.	3.2	6
17	Repurposing the Kinase Inhibitor Mavelertinib for Giardiasis Therapy. Antimicrobial Agents and Chemotherapy, 2022, 66, .	3.2	3
18	High-Content Screening for Cryptosporidium Drug Discovery. Methods in Molecular Biology, 2020, 2052, 303-317.	0.9	2